Prothena(PRTA)
DUBLIN 2, Ireland
BiotechnologyFocus: Antibodies for neuro / immune targets
Prothena is a life sciences company focused on Antibodies for neuro / immune targets.
NeurologyImmunology
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinso
Parkinson's DiseaseClinical Trials (1)
NCT03043768Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson's Disease
N/Anon-interventional
AL AmyloidosisClinical Trials (1)
NCT02574676Quality of Life (QOL) Registry for Patients With AL Amyloidosis
N/APhase 1
Clinical Trials (1)
NCT03336580A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis
Phase 1PRX002
Parkinson's DiseaseClinical Trials (1)
NCT02157714Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease
Phase 1PRX002
Parkinson's DiseaseClinical Trials (1)
NCT02095171Single Ascending Dose Study of PRX002 in Healthy Subjects
Phase 1PRX003
PsoriasisClinical Trials (1)
NCT02630901Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis
Phase 1PRX003
PsoriasisClinical Trials (1)
NCT02458677Single Ascending Dose Study of PRX003 in Healthy Subjects
Phase 1Phase 1
Clinical Trials (1)
NCT06699680Phase 1 Study of PRX019 in Healthy Adult Volunteers
Phase 1NEOD001
Primary AmyloidosisClinical Trials (1)
NCT01707264Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
Phase 1/2NEOD001
AL AmyloidosisClinical Trials (1)
NCT02632786The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
Phase 2Prasinezumab
Parkinsons DiseaseClinical Trials (1)
NCT04777331A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
Phase 2NEOD001
AL AmyloidosisClinical Trials (1)
NCT02613182Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
Phase 2NEOD001
AL AmyloidosisClinical Trials (1)
NCT03154047Study in Subjects With Light Chain (AL) Amyloidosis
Phase 2RO7046015
Parkinson's DiseaseClinical Trials (1)
NCT03100149A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
Phase 2Phase 3
Clinical Trials (1)
NCT02312206The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis
Phase 3Birtamimab
Light Chain (AL) AmyloidosisClinical Trials (1)
NCT04973137A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis
Phase 3Prasinezumab
Parkinson's DiseaseClinical Trials (1)
NCT07174310A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 17 clinical trials
Top TAs: Neurology
SEC Filings: 2 available
Financials (FY2025)
Revenue
$91M70%
R&D Spend
$221M(241%)63%
Net Income
-$147MCash
$619M